New cell therapy targets hard-to-treat cancers with KRAS mutation
Disease control
Not yet recruiting
This early-stage study tests a new treatment called DCTY1102 for people with advanced cancers (like pancreatic, colorectal, or lung cancer) that have a specific genetic change (KRAS/NRAS G12D mutation) and a certain immune type (HLA-A*11:01). The treatment uses the patient's own …
Phase: PHASE1 • Sponsor: Beijing DCTY Biotech Co.,Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:35 UTC